April 30, 2021
According to the research report titled ‘Global newborn screening market 2019-2027’, available with Market Study Report LLC, global newborn screening market is anticipated to grow with a CAGR of 13.76% through 2027.
Rising prevalence of congenital diseases among newborns, increasing awareness related to heart disease in neonatal, and government assistance for health of newborn are bolstering the growth of global newborn screening market. Moreover, increasing number of pregnant women i.e. surge in fertility rate, along with development in technology will also act in favor of market outlook.
Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2487164/
For the record, newborn screening procedures include a set of blood tests with some other tests to look for indications of genetic and endocrine diseases. It is also employed to detect medical conditions like sickle cell disease, galactosemia, phenylketonuria, and congenital hypothyroidism among others. These tests can spot the possibility of diseases at an early stage before the beginning of any clinical symptoms, thereby suggesting early medications & treatments, thus preventing premature death, mental retardation, spasticity, or serious ailments.
On the other side, lack of apt healthcare infrastructure for newborns in developing nations, and socio-economic obstacles in implementing the Newborn Screening Act are the major restraints in the market sphere. Additionally, maintenance of hospital equipment, and lack of skilled medicine practitioners are the factors arresting the expansion matrix of the industry.
Based on product terrain, worldwide newborn screening market is segmented into instruments, and reagents & kits. According to test type, the marketplace is classified into hearing screen test, dry blood spot test, and critical congenital heart disease (CCHD) test. Speaking of technology, the market is divided into tandem mass spectrometry, enzyme-based assays, pulse oximetry, electrophoresis, and DNA-based assays among others.
Moving on to regional outlook, Europe, North America, Latin America, Asia-Pacific, and Middle East & Africa are significant contributors towards worldwide newborn screening market remuneration.
The report cites that North America is poised to hold significant market share by the year 2027, owing to supportive government policies in U.S. and Canada which mandate newborn screening.
Key contenders in global newborn screening industry include Masimo, Agilent Technologies Inc., GE Healthcare, Cardinal Health Inc., Bio-Rad Laboratories Inc., BioTek Instruments Inc., SCIEX, Trivitron Healthcare Pvt. Ltd., Waters Corporation, ZenTech SA, PerkinElmer Inc., NeoGen Labs, Thermo Fisher Scientific, Medtronic plc, and Natus Medical Incorporated.